TYME Provides Business Update and Reports Fourth Quarter and Fiscal Year 2019 Financial and Operating Results
May 29, 2019 09:09 ET
|
Tyme Technologies, Inc.
TYME-88-Panc Continues to Show Encouraging Survival Trend with Additional Data to Be Presented in Third Quarter 2019Single Agent SM-88 (Racemetyrosine) Shown to Have Anti-Tumor Response in Preclinical...
TYME Provides Business Update and Reports Fourth Quarter and Fiscal Year 2019 Financial and Operating Results
May 29, 2019 07:30 ET
|
Tyme Technologies, Inc.
TYME-88-Panc Continues to Show Encouraging Survival Trend with Additional Data to Be Presented in Third Quarter 2019Single Agent SM-88 (racemetyrosine) Shown to Have Anti-Tumor Response in Preclinical...
Tyme Technologies to Present at the Jefferies 2019 Global Healthcare Conference on June 7, 2019
May 28, 2019 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, May 28, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management...
Tyme Technologies To Host a Conference Call for the Fourth Quarter and Fiscal Year 2019 Financial and Operating Results on May 29, 2019
May 24, 2019 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, May 24, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that the company...
TYME and The Joseph Ahmed Foundation Announce Initiation of the HopES Phase II Trial Evaluating the Potential Benefits of SM-88 for Patients with High-Risk Sarcomas
May 23, 2019 08:00 ET
|
Tyme Technologies, Inc.
New oral approach aimed at disrupting cancer metabolism in high-risk sarcomas; 12,000 cases annually in U.S. aloneSM-88 (racemetyrosine) is an oral, investigational cancer metabolism-based therapy...
TYME Announces Notification of Issuance of U.S. Patent Covering SM-88 Single Agent Treatment for Cancers
May 20, 2019 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, May 20, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced today that it...
Tyme Technologies to Participate at the Oppenheimer Oncology Insight Summit on May 16th
May 09, 2019 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, May 09, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management...
Tyme Technologies To Present at BioNJ's 9th Annual BioPartnering Conference on May 8th, 2019
May 02, 2019 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, May 02, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management...
Tyme Technologies to Participate at the SunTrust Robinson Humphrey 5th Annual Life Sciences Summit on May 7th
May 01, 2019 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, May 01, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management...
TYME Announces USAN Approval of Generic Name “Racemetyrosine” for SM-88
April 15, 2019 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, April 15, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced today that...